

Jennifer L Whitwell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/916064/publications.pdf>

Version: 2024-02-01

246
papers

20,384
citations

16437

64
h-index

11928

134
g-index

268
all docs

268
docs citations

268
times ranked

15330
citing authors

#	ARTICLE	IF	CITATIONS
1	The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 27, 685-691.	1.9	2,553
2	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	2.2	1,402
3	A Longitudinal Study of Brain Volume Changes in Normal Aging Using Serial Registered Magnetic Resonance Imaging. <i>Archives of Neurology</i> , 2003, 60, 989.	4.9	736
4	Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. <i>Annals of Neurology</i> , 2001, 49, 433-442.	2.8	641
5	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. <i>Brain</i> , 2006, 129, 1385-1398.	3.7	624
6	3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. <i>Brain</i> , 2007, 130, 1777-1786.	3.7	541
7	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. <i>NeuroImage</i> , 2008, 39, 1186-1197.	2.1	391
8	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. <i>Brain</i> , 2012, 135, 794-806.	3.7	355
9	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. <i>Lancet Neurology</i> , The, 2012, 11, 868-877.	4.9	355
10	Patterns of atrophy in pathologically confirmed FTLN with and without motor neuron degeneration. <i>Neurology</i> , 2006, 66, 102-104.	1.5	351
11	TDP-43 is a key player in the clinical features associated with Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 811-824.	3.9	336
12	Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. <i>Brain</i> , 2012, 135, 1522-1536.	3.7	325
13	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. <i>Brain</i> , 2012, 135, 765-783.	3.7	322
14	Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. <i>Brain</i> , 2007, 130, 708-719.	3.7	286
15	Voxel-Based Morphometry: An Automated Technique for Assessing Structural Changes in the Brain. <i>Journal of Neuroscience</i> , 2009, 29, 9661-9664.	1.7	279
16	Staging TDP-43 pathology in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 441-450.	3.9	278
17	The clinical profile of right temporal lobe atrophy. <i>Brain</i> , 2009, 132, 1287-1298.	3.7	277
18	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. <i>Brain</i> , 2009, 132, 2932-2946.	3.7	277

#	ARTICLE	IF	CITATIONS
19	Corticobasal degeneration: a pathologically distinct 4R tauopathy. <i>Nature Reviews Neurology</i> , 2011, 7, 263-272.	4.9	270
20	Updated TDP-43 in Alzheimer's disease staging scheme. <i>Acta Neuropathologica</i> , 2016, 131, 571-585.	3.9	244
21	Voxel-based morphometry in autopsy proven PSP and CBD. <i>Neurobiology of Aging</i> , 2008, 29, 280-289.	1.5	221
22	Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. <i>Lancet</i> , 2003, 362, 1121-1122.	6.3	190
23	Amyloid burden is not associated with rates of brain atrophy. <i>Annals of Neurology</i> , 2008, 63, 204-212.	2.8	187
24	Patterns of Atrophy Differ Among Specific Subtypes of Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1130.	4.9	185
25	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017, 32, 955-971.	2.2	179
26	Imaging correlates of posterior cortical atrophy. <i>Neurobiology of Aging</i> , 2007, 28, 1051-1061.	1.5	176
27	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 196-203.	0.9	170
28	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. <i>Lancet Neurology</i> , 2017, 16, 917-924.	4.9	159
29	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. <i>NeuroImage</i> , 2014, 94, 65-78.	2.1	155
30	Antemortem MRI based STructural Abnormality INdex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. <i>NeuroImage</i> , 2008, 42, 559-567.	2.1	152
31	Quantitative application of the primary progressive aphasia consensus criteria. <i>Neurology</i> , 2014, 82, 1119-1126.	1.5	147
32	Rates of cerebral atrophy differ in different degenerative pathologies. <i>Brain</i> , 2006, 130, 1148-1158.	3.7	146
33	Disrupted thalamocortical connectivity in PSP: A resting-state fMRI, DTI, and VBM study. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 599-605.	1.1	146
34	Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. <i>Neurology</i> , 2013, 81, 337-345.	1.5	142
35	Measurements of the Amygdala and Hippocampus in Pathologically Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. <i>Archives of Neurology</i> , 2006, 63, 1434.	4.9	139
36	[¹⁸ F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 124-133.	2.2	136

#	ARTICLE	IF	CITATIONS
37	The evolution of primary progressive apraxia of speech. <i>Brain</i> , 2014, 137, 2783-2795.	3.7	134
38	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. <i>Cortex</i> , 2015, 69, 220-236.	1.1	133
39	Magnetic Resonance Imaging Signatures of Tissue Pathology in Frontotemporal Dementia. <i>Archives of Neurology</i> , 2005, 62, 1402.	4.9	132
40	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , 2017, 133, 705-715.	3.9	125
41	VBM signatures of abnormal eating behaviours in frontotemporal lobar degeneration. <i>NeuroImage</i> , 2007, 35, 207-213.	2.1	122
42	Volumetric MRI and cognitive measures in Alzheimer disease. <i>Journal of Neurology</i> , 2008, 255, 567-574.	1.8	121
43	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	2.2	121
44	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. <i>Acta Neuropathologica</i> , 2016, 132, 931-933.	3.9	116
45	Clinical Correlates of White Matter Tract Degeneration in Progressive Supranuclear Palsy. <i>Archives of Neurology</i> , 2011, 68, 753-60.	4.9	110
46	Prosodic and phonetic subtypes of primary progressive apraxia of speech. <i>Brain and Language</i> , 2018, 184, 54-65.	0.8	106
47	Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. <i>Neurobiology of Aging</i> , 2011, 32, 1531-1541.	1.5	105
48	FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimer's Type. <i>PLoS ONE</i> , 2013, 8, e62471.	1.1	100
49	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 1144-1153.	2.2	98
50	TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. <i>Annals of Neurology</i> , 2015, 78, 697-709.	2.8	96
51	Fluorodeoxyglucose F18 Positron Emission Tomography in Progressive Apraxia of Speech and Primary Progressive Aphasia Variants. <i>Archives of Neurology</i> , 2010, 67, 596-605.	4.9	93
52	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	2.2	93
53	¹⁸ F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. <i>Journal of Nuclear Medicine</i> , 2017, 58, 632-638.	2.8	91
54	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. <i>NeuroImage</i> , 2011, 55, 522-531.	2.1	90

#	ARTICLE	IF	CITATIONS
55	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. <i>Neurobiology of Aging</i> , 2015, 36, 1245-1252.	1.5	83
56	Voxel-Based Morphometry in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With and Without Progranulin Mutations. <i>Archives of Neurology</i> , 2007, 64, 371.	4.9	82
57	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1005-1014.	0.4	80
58	Neuropsychological Profiles Differ among the Three Variants of Primary Progressive Aphasia. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 429-435.	1.2	78
59	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	3.7	74
60	[¹⁸ F]AV β 1451 tau-PET and primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 83, 599-611.	2.8	73
61	Comparisons Between Alzheimer Disease, Frontotemporal Lobar Degeneration, and Normal Aging With Brain Mapping. <i>Topics in Magnetic Resonance Imaging</i> , 2005, 16, 409-425.	0.7	71
62	Anatomical differences between CBS corticobasal degeneration and CBS Alzheimer's disease. <i>Movement Disorders</i> , 2010, 25, 1246-1252.	2.2	71
63	Longitudinal Patterns of Regional Change on Volumetric MRI in Frontotemporal Lobar Degeneration. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 307-310.	0.7	70
64	Visual Hallucinations in Posterior Cortical Atrophy. <i>Archives of Neurology</i> , 2006, 63, 1427.	4.9	70
65	Progranulin-associated PiB-negative logopenic primary progressive aphasia. <i>Journal of Neurology</i> , 2014, 261, 604-614.	1.8	69
66	Primary Progressive Apraxia of Speech: Clinical Features and Acoustic and Neurologic Correlates. <i>American Journal of Speech-Language Pathology</i> , 2015, 24, 88-100.	0.9	69
67	[¹⁸ F]AV β 1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 83, 248-257.	2.8	67
68	Progression of Atrophy in Alzheimer's Disease and Related Disorders. <i>Neurotoxicity Research</i> , 2010, 18, 339-346.	1.3	66
69	Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: An MRI and FDG-PET study. <i>Brain and Language</i> , 2013, 125, 245-252.	0.8	66
70	Neuroimaging in frontotemporal lobar degeneration—predicting molecular pathology. <i>Nature Reviews Neurology</i> , 2012, 8, 131-142.	4.9	65
71	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. <i>Acta Neuropathologica</i> , 2019, 137, 227-238.	3.9	65
72	Nonverbal oral apraxia in primary progressive aphasia and apraxia of speech. <i>Neurology</i> , 2014, 82, 1729-1735.	1.5	63

#	ARTICLE	IF	CITATIONS
73	Imaging Signatures of Molecular Pathology in Behavioral Variant Frontotemporal Dementia. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 372-8.	1.1	61
74	Comparison of Imaging Biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. <i>Archives of Neurology</i> , 2012, 69, 614.	4.9	60
75	FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. <i>Journal of Neurology</i> , 2014, 261, 710-716.	1.8	60
76	Association of Apolipoprotein E ϵ 4 With Transactive Response DNA-Binding Protein 43. <i>JAMA Neurology</i> , 2018, 75, 1347.	4.5	60
77	Symmetric corticobasal degeneration (S-CBD). <i>Parkinsonism and Related Disorders</i> , 2010, 16, 208-214.	1.1	56
78	Temporal acoustic measures distinguish primary progressive apraxia of speech from primary progressive aphasia. <i>Brain and Language</i> , 2017, 168, 84-94.	0.8	56
79	Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. <i>Neurobiology of Aging</i> , 2013, 34, 636-639.	1.5	54
80	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 23, 101823.	1.4	54
81	Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimer's disease presenting as logopenic progressive aphasia. <i>Brain and Language</i> , 2013, 127, 127-134.	0.8	53
82	Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. <i>Journal of Neurology</i> , 2015, 262, 1483-1492.	1.8	53
83	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 1618-1631.	1.9	53
84	Frontotemporal Lobar Degeneration Without Lobar Atrophy. <i>Archives of Neurology</i> , 2006, 63, 1632.	4.9	52
85	Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease. <i>NeuroImage</i> , 2008, 39, 1034-1040.	2.1	52
86	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. <i>Neurobiology of Aging</i> , 2019, 77, 26-36.	1.5	51
87	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. <i>Brain</i> , 2020, 143, 2281-2294.	3.7	51
88	Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: Determining sample size for treatment trials. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 252-256.	1.1	49
89	Identification of an atypical variant of logopenic progressive aphasia. <i>Brain and Language</i> , 2013, 127, 139-144.	0.8	49
90	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 493-498.	1.1	49

#	ARTICLE	IF	CITATIONS
91	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. <i>Brain and Language</i> , 2015, 142, 45-53.	0.8	49
92	MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration. <i>Neurodegenerative Diseases</i> , 2009, 6, 106-117.	0.8	47
93	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. <i>NeuroImage: Clinical</i> , 2020, 25, 102152.	1.4	46
94	Predicting functional decline in behavioural variant frontotemporal dementia. <i>Brain</i> , 2011, 134, 432-448.	3.7	45
95	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1713-1724.	1.2	45
96	Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy. <i>Brain</i> , 2020, 143, 3463-3476.	3.7	45
97	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. <i>NeuroImage: Clinical</i> , 2013, 2, 249-257.	1.4	44
98	LATE to the PART-y. <i>Brain</i> , 2019, 142, e47-e47.	3.7	44
99	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. <i>Cerebral Cortex</i> , 2021, 31, 1693-1706.	1.6	44
100	A Volumetric Magnetic Resonance Imaging Study of the Amygdala in Frontotemporal Lobar Degeneration and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 238-244.	0.7	43
101	Gray matter correlates of behavioral severity in progressive supranuclear palsy. <i>Movement Disorders</i> , 2011, 26, 493-498.	2.2	43
102	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. <i>Cortex</i> , 2018, 99, 358-374.	1.1	42
103	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. <i>Brain</i> , 2018, 141, 302-317.	3.7	42
104	Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. <i>Nature Reviews Neurology</i> , 2021, 17, 601-620.	4.9	41
105	Anatomic correlates of stereotypies in frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2008, 29, 1859-1863.	1.5	40
106	Recent Advances in the Imaging of Frontotemporal Dementia. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 715-723.	2.0	39
107	Neuropsychiatric Symptoms in Primary Progressive Aphasia and Apraxia of Speech. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 228-238.	0.7	38
108	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. <i>Brain</i> , 2013, 136, 455-470.	3.7	37

#	ARTICLE	IF	CITATIONS
109	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. <i>Brain</i> , 2019, 142, 3621-3635.	3.7	37
110	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	2.2	37
111	Modeling trajectories of regional volume loss in progressive supranuclear palsy. <i>Movement Disorders</i> , 2013, 28, 1117-1124.	2.2	36
112	Disrupted functional connectivity in primary progressive apraxia of speech. <i>NeuroImage: Clinical</i> , 2018, 18, 617-629.	1.4	36
113	Clinical Progression in Four Cases of Primary Progressive Apraxia of Speech. <i>American Journal of Speech-Language Pathology</i> , 2018, 27, 1303-1318.	0.9	36
114	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 675-685.	0.4	36
115	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. <i>Nature Communications</i> , 2021, 12, 3452.	5.8	34
116	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. <i>Brain</i> , 2019, 142, 2466-2482.	3.7	33
117	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2019, 34, 105-113.	2.2	33
118	The pimple sign of progressive supranuclear palsy syndrome. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 180-185.	1.1	32
119	Dominant Frontotemporal Dementia Mutations in 140 Cases of Primary Progressive Aphasia and Speech Apraxia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 281-286.	0.7	32
120	Sensitivityâ€Specificity of Tau and Amyloid Î² Positron Emission Tomography in Frontotemporal Lobar Degeneration. <i>Annals of Neurology</i> , 2020, 88, 1009-1022.	2.8	32
121	<i>APOE</i> Î¼4 influences Î²â€amyloid deposition in primary progressive aphasia and speech apraxia. <i>Alzheimer's and Dementia</i> , 2014, 10, 630-636.	0.4	31
122	Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. <i>Annals of Neurology</i> , 2006, 59, 200-203.	2.8	30
123	Voxel-based morphometry and its application to movement disorders. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S406-S416.	1.1	30
124	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. <i>Neurology</i> , 2017, 89, 2271-2279.	1.5	30
125	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. <i>Brain and Language</i> , 2019, 197, 104676.	0.8	29
126	Elevated occipital Î²-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1357-1364.	0.9	28

#	ARTICLE	IF	CITATIONS
127	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 633-643.	1.2	27
128	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 3-9.	1.1	27
129	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. <i>Neurology</i> , 2020, 95, e23-e34.	1.5	27
130	Patterns of Neuropsychological Dysfunction and Cortical Volume Changes in Logopenic Aphasia. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1015-1025.	1.2	26
131	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 452-461.	0.8	26
132	¹⁸ F-AV-1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , 2019, 34, 344-352.	2.2	26
133	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. <i>Neurocase</i> , 2018, 24, 111-120.	0.2	25
134	FTD spectrum: Neuroimaging across the FTD spectrum. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 165, 187-223.	0.9	25
135	Dysphagia in Progressive Supranuclear Palsy. <i>Dysphagia</i> , 2020, 35, 667-676.	1.0	25
136	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1019-1029.	1.2	24
137	Alzheimer's disease neuroimaging. <i>Current Opinion in Neurology</i> , 2018, 31, 396-404.	1.8	24
138	Corticobasal degeneration. <i>International Review of Neurobiology</i> , 2019, 149, 87-136.	0.9	24
139	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	2.1	24
140	Western Aphasia Battery—Revised Profiles in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech. <i>American Journal of Speech-Language Pathology</i> , 2020, 29, 498-510.	0.9	24
141	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. <i>Cortex</i> , 2017, 90, 138-148.	1.1	22
142	Atrophy in midbrain & cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy—A double-validation whole-brain meta-analysis. <i>NeuroImage: Clinical</i> , 2019, 22, 101722.	1.4	22
143	Voxel-Based Morphometry in Tau-Positive and Tau-Negative Frontotemporal Lobar Degenerations. <i>Neurodegenerative Diseases</i> , 2004, 1, 225-230.	0.8	21
144	Ideomotor apraxia in agrammatic and logopenic variants of primary progressive aphasia. <i>Journal of Neurology</i> , 2013, 260, 1594-1600.	1.8	21

#	ARTICLE	IF	CITATIONS
145	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. <i>Annals of Neurology</i> , 2021, 89, 520-533.	2.8	21
146	Neuroimaging in Dementia. <i>Neurologic Clinics</i> , 2007, 25, 843-857.	0.8	20
147	Right temporal variant frontotemporal dementia with motor neuron disease. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 85-91.	0.8	20
148	TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnesic Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1227-1233.	1.2	20
149	The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 34-40.	1.1	20
150	Imaging measures predict progression in progressive supranuclear palsy. <i>Movement Disorders</i> , 2012, 27, 1801-1804.	2.2	19
151	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1109-1117.	1.2	19
152	Quantitative Analysis of Agrammatism in Agrammatic Primary Progressive Aphasia and Dominant Apraxia of Speech. <i>Journal of Speech, Language, and Hearing Research</i> , 2018, 61, 2337-2346.	0.7	19
153	Multimodal neuroimaging relationships in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 56-61.	1.1	19
154	Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 29-35.	1.1	18
155	Coprophagia in neurologic disorders. <i>Journal of Neurology</i> , 2016, 263, 1008-1014.	1.8	18
156	Characterization of a Family With c9FTD/ALS Associated With the GGGGCC Repeat Expansion in C9ORF72. <i>Archives of Neurology</i> , 2012, 69, 1164-9.	4.9	17
157	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	1.7	17
158	Neuroanatomical correlates of phonologic errors in logopenic progressive aphasia. <i>Brain and Language</i> , 2020, 204, 104773.	0.8	15
159	Using nine degrees-of-freedom registration to correct for changes in voxel size in serial MRI studies. <i>Magnetic Resonance Imaging</i> , 2004, 22, 993-999.	1.0	14
160	Microbleeds in the logopenic variant of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2014, 10, 62-66.	0.4	14
161	Tau Imaging in Parkinsonism: What Have We Learned So Far?. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 118-130.	0.8	14
162	Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa. <i>Alzheimer's and Dementia</i> , 2019, 15, 799-806.	0.4	14

#	ARTICLE	IF	CITATIONS
163	Prominent auditory deficits in primary progressive aphasia: A case study. <i>Cortex</i> , 2019, 117, 396-406.	1.1	14
164	Automated Hippocampal Subfield Volumetric Analyses in Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 927-937.	1.2	14
165	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1511-1523.	1.2	14
166	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	2.4	14
167	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2022, 37, 702-712.	2.2	14
168	Longitudinal imaging: change and causality. <i>Current Opinion in Neurology</i> , 2008, 21, 410-416.	1.8	13
169	Association between transactive response DNA-binding protein of 43 kDa type and cognitive resilience to Alzheimer's disease: a case-control study. <i>Neurobiology of Aging</i> , 2020, 92, 92-97.	1.5	13
170	Communication Limitations in Patients With Progressive Apraxia of Speech and Aphasia. <i>American Journal of Speech-Language Pathology</i> , 2020, 29, 1976-1986.	0.9	13
171	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. <i>Neurology</i> , 2020, 95, e3190-e3202.	1.5	13
172	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2021, 32, 102850.	1.4	13
173	Aphasia with left occipitotemporal hypometabolism: A novel presentation of posterior cortical atrophy?. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 1237-1240.	0.8	12
174	Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. <i>Journal of Neurology</i> , 2020, 267, 2603-2611.	1.8	12
175	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. <i>Journal of Neurology</i> , 2021, 268, 3409-3420.	1.8	12
176	Motor Speech Disorders and Communication Limitations in Progressive Supranuclear Palsy. <i>American Journal of Speech-Language Pathology</i> , 2021, 30, 1361-1372.	0.9	12
177	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. <i>Brain Communications</i> , 2021, 3, fcab182.	1.5	12
178	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. <i>Neurology</i> , 2022, 98, .	1.5	12
179	The protective role of brain size in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1799-1801.	1.4	11
180	Primary lateral sclerosis as progressive supranuclear palsy: Diagnosis by diffusion tensor imaging. <i>Movement Disorders</i> , 2012, 27, 903-906.	2.2	11

#	ARTICLE	IF	CITATIONS
181	Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia. <i>Neurocase</i> , 2016, 22, 55-59.	0.2	11
182	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. <i>Neurobiology of Aging</i> , 2021, 108, 90-98.	1.5	11
183	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. <i>NeuroImage: Clinical</i> , 2022, 34, 102999.	1.4	11
184	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. <i>Journal of Neurology</i> , 2015, 262, 2064-2072.	1.8	10
185	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. <i>NeuroImage: Clinical</i> , 2016, 11, 90-98.	1.4	10
186	The influence of β -amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. <i>Neurology</i> , 2019, 92, e710-e722.	1.5	10
187	Old age genetically confirmed frontotemporal lobar degeneration with TDP β 43 has limbic predominant TDP β 43 deposition. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 1050-1059.	1.8	10
188	Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years. <i>Neurology</i> , 2022, 98, .	1.5	10
189	Electroencephalography in primary progressive aphasia and apraxia of speech. <i>Aphasiology</i> , 2019, 33, 1410-1417.	1.4	9
190	Relationship Between ¹⁸ F-Flortaucipir Uptake and Histologic Lesion Types in 4-Repeat Tauopathies. <i>Journal of Nuclear Medicine</i> , 2022, 63, 931-935.	2.8	9
191	Survival Analysis in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. <i>Neurology: Clinical Practice</i> , 2021, 11, 249-255.	0.8	9
192	Focal brain atrophy in gastric bypass patients with cognitive complaints. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1671-1676.	0.8	8
193	Phonological Errors in Posterior Cortical Atrophy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 195-203.	0.7	8
194	Medial Temporal Atrophy in Posterior Cortical Atrophy and Its Relationship to the Cingulate Island Sign. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 491-498.	1.2	8
195	Depression and Apathy across Different Variants of Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 212-217.	0.8	8
196	Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant. <i>NeuroImage: Clinical</i> , 2022, 35, 103030.	1.4	8
197	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	1.2	7
198	Quantitative assessment of grammar in amyloid-negative logopenic aphasia. <i>Brain and Language</i> , 2018, 186, 26-31.	0.8	7

#	ARTICLE	IF	CITATIONS
199	Longitudinal Amyloid- β PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 377-389.	1.2	7
200	A Longitudinal Evaluation of Speech Rate in Primary Progressive Apraxia of Speech. <i>Journal of Speech, Language, and Hearing Research</i> , 2021, 64, 392-404.	0.7	7
201	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 683-693.	1.2	7
202	Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. <i>Neurology</i> , 2021, 97, 908-909.	1.5	7
203	Posterior cortical atrophy: Primary occipital variant. <i>European Journal of Neurology</i> , 2022, 29, 2138-2143.	1.7	7
204	<i>APOE</i> ϵ 4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 784-796.	0.4	7
205	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. <i>Neurocase</i> , 2020, 26, 259-263.	0.2	6
206	Autopsy Validation of Progressive Supranuclear Palsy's Predominant Speech/Language Disorder Criteria. <i>Movement Disorders</i> , 2022, 37, 213-218.	2.2	6
207	Rapid rate on quasi-speech tasks in the semantic variant of primary progressive aphasia: A non-motor phenomenon?. <i>Journal of the Acoustical Society of America</i> , 2018, 144, 3364-3370.	0.5	5
208	Longitudinal flortaucipir ([18 F]AV-1451) PET imaging in primary progressive apraxia of speech. <i>Cortex</i> , 2020, 124, 33-43.	1.1	5
209	Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 17-28.	0.7	5
210	Progressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses. <i>Journal of Neurology</i> , 2021, 268, 4752-4758.	1.8	5
211	Neurodegeneration of the visual word form area in a patient with word form alexia. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 359-360.	0.2	5
212	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. <i>Brain Communications</i> , 2022, 4, .	1.5	5
213	Non-right handed primary progressive apraxia of speech. <i>Journal of the Neurological Sciences</i> , 2018, 390, 246-254.	0.3	4
214	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. <i>Journal of Neurology</i> , 2020, 267, 1444-1453.	1.8	4
215	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. <i>Neurocase</i> , 2021, 27, 212-222.	0.2	4
216	Update on neuroimaging in Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2021, 34, 525-531.	1.8	4

#	ARTICLE	IF	CITATIONS
217	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphereâ€Predominant Logopenic Progressive Aphasia. <i>Neurology</i> , 2021, 97, e523-e534.	1.5	4
218	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 2669-2675.	2.2	4
219	Laboratory based assessment of gait and balance impairment in patients with progressive supranuclear palsy. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118054.	0.3	4
220	Sleep disturbances in the speech-language variant of progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 9-12.	1.1	4
221	In vivo imaging and autoradiography in a case of autopsy-confirmed Pick disease. <i>Neurology: Clinical Practice</i> , 2021, 11, 10.1212/CPJ.0000000000000755.	0.8	4
222	Multimodal neuroimaging provides insights into the biology of Alzheimerâ€™s disease. <i>Brain</i> , 2018, 141, 326-329.	3.7	3
223	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. <i>Neurobiology of Aging</i> , 2020, 92, 135-140.	1.5	3
224	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2022, 34, 102954.	1.4	3
225	Neuroimaging in Dementia. <i>PET Clinics</i> , 2007, 2, 15-24.	1.5	2
226	Tauopathies. , 2013, , 147-166.		2
227	Brain tau deposition linked to systemic causes of death in normal elderly. <i>Neurobiology of Aging</i> , 2017, 50, 163-166.	1.5	2
228	Molecular neuroimaging in primary progressive aphasia with predominant agraphia. <i>Neurocase</i> , 2018, 24, 121-123.	0.2	2
229	Assessing Subtle Structural Changes in Alzheimerâ€™s Disease Patients. <i>Methods in Molecular Biology</i> , 2011, 711, 535-550.	0.4	2
230	Dynamic Aphasia as a Variant of Frontotemporal Dementia. <i>Cognitive and Behavioral Neurology</i> , 2021, 34, 303-318.	0.5	2
231	Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 9-14.	1.1	2
232	NEUROIMAGING IN DEMENTIA. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2007, 13, 180-203.	0.4	1
233	Progressive Apraxia of Speech and Primary Progressive Aphasias. , 2014, , 213-230.		1
234	Uncovering Neuroanatomical Networks Responsible for Abnormal Eating Behavior in Frontotemporal Dementia. <i>JAMA Neurology</i> , 2016, 73, 267.	4.5	1

#	ARTICLE	IF	CITATIONS
235	Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia. Journal of the International Neuropsychological Society, 2022, 28, 441-451.	1.2	1
236	A Preliminary Report of Network Electroencephalographic Measures in Primary Progressive Apraxia of Speech and Aphasia. Brain Sciences, 2022, 12, 378.	1.1	1
237	Relationship of <i>APOE</i> , age, amyloid and clinical phenotype in Alzheimer disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
238	Cross-Sectional and Longitudinal Assessment of Behavior in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. Dementia and Geriatric Cognitive Disorders, 2022, 51, 193-202.	0.7	1
239	Imaging brain atrophy in progressive supranuclear palsy and corticobasal syndromes: potential for diagnosis and monitoring of disease progression. Neurodegenerative Disease Management, 2012, 2, 589-598.	1.2	0
240	ICâ€Pâ€201: Predicting Amyloid Deposition in Progressive Aphasia and Apraxia of Speech Using Clinical and Mri Data. Alzheimer's and Dementia, 2016, 12, P144.	0.4	0
241	ICâ€Pâ€203: AVâ€1451 TAUâ€PET Binding in Typical and Atypical Syndromic Variants of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P145.	0.4	0
242	[ICâ€Pâ€204]: SUBJECTâ€LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAUâ€PET, AMYLOIDâ€PET, MRI AND FDGâ€PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P149.	0.4	0
243	[O1â€06â€05]: SUBJECTâ€LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAUâ€PET, AMYLOIDâ€PET, MRI AND FDGâ€PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P203.	0.4	0
244	ICâ€Pâ€083: DIAGNOSTIC UTILITY OF [18F]AVâ€1451 PET, FDGâ€PET AND MRI TO DIFFERENTIATE THE THREE VARIANTS OF PRIMARY PROGRESSIVE APHASIA. Alzheimer's and Dementia, 2018, 14, P71.	0.4	0
245	ICâ€02â€05: THE INFLUENCE OF AGE ON REGIONAL [¹⁸ F]AVâ€1451 PET, PITTSBURGH COMPOUND B PET AND MRI ATROPHY IN ATYPICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P6.	0.4	0
246	Heterogeneity in imagingâ€based spread of tau and atrophy in atypical AD. Alzheimer's and Dementia, 2021, 17, .	0.4	0